Dr. Claudia Fox, MD

NPI: 1306877709
Total Payments
$30,960
2024 Payments
$30,955
Companies
3
Transactions
9

Payment Breakdown by Category

Travel$14,870 (48.0%)
Research$14,488 (46.8%)
Other$1,567 (5.1%)
Food & Beverage$29.67 (0.1%)
Consulting$5.15 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Travel and Lodging $14,870 3 48.0%
Unspecified $14,488 2 46.8%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,567 2 5.1%
Food and Beverage $29.67 1 0.1%
Consulting Fee $5.15 1 0.0%

Payments by Type

General
$16,473
7 transactions
Research
$14,488
2 transactions

Top Paying Companies

Company Total Records Latest Year
Novo Nordisk AS $16,467 6 $0 (2024)
Eli Lilly and Company $14,488 2 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $30,955 8 Novo Nordisk AS ($16,467)
2022 $5.15 1 KVK-Tech, Inc. ($5.15)

All Payment Transactions

9 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
11/16/2024 Novo Nordisk AS Saxenda (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $681.67 General
Category: Obesity
09/24/2024 Eli Lilly and Company Cash or cash equivalent $14,466.00 Research
Study: A STUDY OF TIRZEPATIDE (LY3298176) ONCE WEEKLY IN ADOLESCENT PARTICIPANTS WHO HAVE OBESITY, OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES
09/09/2024 Novo Nordisk AS Saxenda (Drug) Travel and Lodging In-kind items and services $13,209.39 General
Category: Obesity
09/09/2024 Novo Nordisk AS Saxenda (Drug) Travel and Lodging In-kind items and services $1,263.21 General
Category: Obesity
09/09/2024 Novo Nordisk AS Saxenda (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $885.65 General
Category: Obesity
09/09/2024 Novo Nordisk AS Saxenda (Drug) Travel and Lodging In-kind items and services $397.80 General
Category: Obesity
09/09/2024 Novo Nordisk AS Saxenda (Drug) Food and Beverage In-kind items and services $29.67 General
Category: Obesity
01/29/2024 Eli Lilly and Company In-kind items and services $21.70 Research
Study: A STUDY OF TIRZEPATIDE (LY3298176) ONCE WEEKLY IN ADOLESCENT PARTICIPANTS WHO HAVE OBESITY, OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES
06/22/2022 KVK-Tech, Inc. Consulting Fee Cash or cash equivalent $5.15 General

Research Studies & Clinical Trials

Study Name Company Amount Records
A STUDY OF TIRZEPATIDE (LY3298176) ONCE WEEKLY IN ADOLESCENT PARTICIPANTS WHO HAVE OBESITY, OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES Eli Lilly and Company $14,488 2

About Dr. Claudia Fox, MD

Dr. Claudia Fox, MD is a Pediatrics healthcare provider based in Minneapolis, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306877709.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Claudia Fox, MD has received a total of $30,960 in payments from pharmaceutical and medical device companies, with $30,955 received in 2024. These payments were reported across 9 transactions from 3 companies. The most common payment nature is "Travel and Lodging" ($14,870).

Practice Information

  • Specialty Pediatrics
  • Location Minneapolis, MN
  • Active Since 07/05/2006
  • Last Updated 07/08/2007
  • Taxonomy Code 208000000X
  • Entity Type Individual
  • NPI Number 1306877709

Products in Payments

  • Saxenda (Drug) $16,467

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatrics Doctors in Minneapolis